<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53555">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01786031</url>
  </required_header>
  <id_info>
    <org_study_id>2012-A00668-35</org_study_id>
    <nct_id>NCT01786031</nct_id>
  </id_info>
  <brief_title>Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program</brief_title>
  <acronym>PETRUS</acronym>
  <official_title>Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Toward personalised treatment in early metastatic prostate cancer based on the assessment of
      biomarkers in cancer tissue samples and circulating tumour cells.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Biomarker</measure>
    <time_frame>assessed at the end of recruitment, up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>success to evaluate at least one molecular analysis in tumor tissues (prostate and/or metastatic site) AND in CTC</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Metastatic Castration Resistant Prostate Cancer Patients</condition>
  <arm_group>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metastasis biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>metastasis biopsy</intervention_name>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prostate Cancer patients

          -  Castration Resistant

          -  Prostatic tissue available

          -  Metastasis which may be biopsied

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christophe Massard</last_name>
    <phone>33 1 42 11 43 38</phone>
    <email>christophe.massard@igr.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Massard</last_name>
      <phone>142114338</phone>
      <phone_ext>+33</phone_ext>
      <email>christophe.massard@igr.fr</email>
    </contact>
    <contact_backup>
      <last_name>Aurélie ABOU LOVERGNE</last_name>
      <phone>142116250</phone>
      <phone_ext>+33</phone_ext>
      <email>aurelie.aboulovergne@igr.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Christophe Massard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>February 6, 2013</lastchanged_date>
  <firstreceived_date>December 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
